CCSD code 0040G: MRD genomic sequencing for blood cancers

Key Takeaways

CCSD code 0040G is the CCSD Schedule code for MRD (measurable/minimal residual disease) genomic sequencing in blood cancers — a next-generation sequencing test that monitors leukemia, lymphoma, and myeloma patients for residual disease after treatment.

The code sits within CCSD Chapter 34 (Pathology) — the code set the CCSD Group maintains for UK private medical insurance (PMI) billing. Chapter 34 pathology codes use a different numbering structure from the rest of the schedule (a numeric stem plus a specimen-type letter, per the NHS National Laboratory Medicine Catalogue), so 0040G’s exact placement is worth confirming via the official CCSD schedule or your insurer rather than assumed.

Bupa, AXA Health, Aviva, Vitality, Healix, and Allianz Care all recognize CCSD code 0040G, but pre-authorization is close to mandatory: a molecular pathology test at this price point gets far more scrutiny than routine bloodwork.

Because MRD monitoring is billed round after round for the same patient, the claims that clear cleanly share three habits: pre-authorization tied to the specific diagnosis, invoice wording that matches the CCSD schedule exactly, and authorization references tracked by test date rather than just by patient.

CCSD code 0040G is the code independent pathology labs use to bill UK private medical insurers for MRD genomic sequencing in blood cancers. Simple enough on paper. In practice, it’s one of the pathology codes most likely to be coded correctly and still come back unpaid.

It belongs to the CCSD Schedule, the coding system the CCSD Group maintains for UK private healthcare billing — but the code itself is the easy part. What decides whether a 0040G claim clears is everything wrapped around it: the pre-authorization, the exact invoice wording, the lab’s recognition status, and the fact that the same patient is billed for it round after round.

So before anything else, it’s worth being clear on what you’re actually billing for — starting with what the test does.

CCSD code 0040G: Definition and clinical context

MRD testing answers one blunt clinical question. After a patient has been treated for leukemia, lymphoma, or myeloma, has the treatment actually cleared the malignant cells — or are a few still hiding, below the level anything routine would catch?

The “few still hiding” part is where the sensitivity of the test earns its keep, and it helps to see the ladder. Conventional morphology under a microscope picks up disease down to roughly 1 in 100 cells (10⁻²). Standard multiparameter flow cytometry does far better, catching residual cells at around 1 in 10,000 (10⁻⁴) — two orders of magnitude sharper. Next-generation flow cytometry pushes further, into the 1 in 100,000 to 1,000,000 range.

Genomic sequencing — the NGS-based approach 0040G covers — sits at the far end, around 1 in a million (10⁻⁶). At that depth it flags residual clones that would otherwise stay invisible until they’d grown back into a full relapse.

Which is exactly why it’s ordered on a schedule, not once. A baseline sequence at diagnosis, then repeat tests at fixed points — post-induction, post-transplant, through maintenance — each one hunting for a molecular relapse months before a scan or a blood count would show anything. Every one of those rounds is a separate 0040G claim, and that repetition shapes almost everything about how the code is billed. Hold onto it; it comes back at claims submission.

It’s often clinicians moving from the NHS into independent private practice — including nurse practitioners building their own referral pathways — who meet CCSD codes for the first time right here, setting up billing for tests they’d previously ordered without ever seeing an invoice.

Where 0040G sits in the CCSD Schedule

The CCSD Schedule is organized by chapter, and 0040G lives in Chapter 34 — Pathology.

Chapter 34 doesn’t follow the same numbering logic as the rest of the schedule. Per CCSD’s own Technical Guide & Business Rules, its codes are drawn from the NHS National Laboratory Medicine Catalogue, and they pair a numeric stem with a trailing letter that flags the specimen type.

The documented specimen letters run A (calculus) through U (urine), and “G” isn’t on that list.

What’s safe to say: Chapter 34 spans a broad range of lab diagnostics, and genomic sequencing for residual-disease monitoring is billed inside that pathology chapter, alongside other molecular oncology tests such as CCSD code 0042G, CCSD code 0022G, and CCSD code 0006G — though we can’t confirm they share the same specimen-letter grouping.

For the exact placement and current definition of 0040G, go to the source: the official CCSD schedule (login required) or the insurer processing the claim. Don’t lean on a category label that isn’t published anywhere you can check.

Insurers assign their fee columns by chapter and by the provider’s recognition status, so what actually has to line up is the insurer’s system and the lab’s Chapter 34 pathology recognition, not anyone’s gut sense of where a genomic test “should” sit. Which brings us to the insurers themselves.

Which UK private medical insurers recognize CCSD code 0040G

Bupa, AXA Health, Aviva, Vitality Health, Healix, and Allianz Care all accept CCSD code 0040G as a valid Chapter 34 pathology code.

At this price point, a molecular pathology test draws the kind of scrutiny a routine blood panel never does. Most insurers handle it more like a scan or a specialist procedure than a lab test, which makes the terms below worth reading before you commit a sample to sequencing.

Read across that table and a pattern jumps out: not one of them will take a bare code and a membership number. They want the specific hematological diagnosis, which treatment phase the test is monitoring, and the referring consultant’s name upfront.

Skip the clinical context and you’ll usually get a query rather than a flat rejection. That sounds better than it is. A query still parks the payment for weeks while someone chases down the detail that should have been on the claim in the first place.

Fee rates and reimbursement for 0040G

Fees for 0040G vary by insurer, and like most of Chapter 34 they sit toward the top of the pathology scale.

There’s no single published rate to memorize. Each insurer sets its own benefit maximum, and each one moves. Look it up per insurer, per claim, before you invoice; last year’s figure is a guess, not a rate.

Some insurers set the benefit maximum below what an independent lab charges for the full panel, and if the test is a covered benefit, that shortfall isn’t automatically something you can bill back to the patient. Before you run an MRD panel for an insured patient, read your recognition terms, and read the balance-billing clauses in particular.

How to submit a claim using 0040G

1. Get pre-authorization tied to the diagnosis. Call the insurer before the sample goes for sequencing. Give them CCSD code 0040G, the membership number, the treating hematologist’s or oncologist’s referral, and the exact blood-cancer diagnosis the test is monitoring. High-cost genomic tests submitted without an authorization reference get queried almost by default.
2. Confirm the lab’s own recognition status. The lab or provider has to be recognized for Chapter 34 pathology billing specifically. Recognition earned for consultant procedures elsewhere in the schedule doesn’t carry over to it.
3. Link the request to the clinical record. Before the invoice goes out, record the referring consultant’s request, the diagnosis, and the sample details against the patient file. Insurers ask for this on genomic tests far more often than on routine bloodwork, and it’s miserable to reconstruct after a query has already landed.
4. Raise the invoice with matching wording. Include the membership number, the authorization reference, the date of service, CCSD code 0040G, and a procedure description that matches the official CCSD schedule wording exactly.
5. Submit through Healthcode. Upload via the Healthcode portal or integrated practice management software. Healthcode validates the claim format before passing it to the insurer. Keep the submission reference.
6. Track each round on its own. Because MRD monitoring is billed episodically, log authorization references by test date, not just by patient. That way a query on round three never gets tangled up with the authorization for round one.

CCSD code 0040G vs OPCS-4: Why this pathology test isn’t a surgical code

People new to CCSD coding often ask how a code maps to OPCS-4. For 0040G, the honest answer is that it doesn’t. OPCS-4 is the NHS classification for surgical and interventional procedures, the codes behind Hospital Episode Statistics. It was never built for lab diagnostics. MRD sequencing is a test run on a blood or bone marrow sample, not an operation, so it only ever lives on the pathology side of the schedule.

Common billing errors when using 0040G

0040G claims get rejected for a short, predictable list of reasons, and nearly all of them trace back to the same three things that make this code unusual: where it sits, what it costs, and how often it’s billed for one patient.

Here’s what to watch for.

• Filing under the wrong chapter. 0040G sits within Chapter 34 pathology, not a genetics or histopathology heading elsewhere in the schedule. Filing it under the wrong chapter throws off the fee column an insurer applies, even when the digits on the invoice are correct.
• Reaching for an OPCS-4 code. There isn’t one to reach for (OPCS-4 doesn’t cover laboratory tests), but a lab used to NHS-style coding sometimes tries to force an NHS code onto a private invoice anyway. It’s an automatic rejection.
• Missing pre-authorization for the genomic test specifically. A general pre-auth for “bloodwork” or “monitoring” doesn’t cover a named molecular pathology test. Insurers want 0040G authorized by name and tied to the diagnosis.
• Unbundling from an existing monitoring panel. If a patient’s monitoring already includes a bundled panel covering residual disease testing, billing 0040G again as a separate line is unbundling. Check the insurer’s bundling rules for hematology monitoring panels before invoicing it on its own.
• Wording that doesn’t match the schedule. Describing the test as “NGS MRD panel” or “molecular residual disease screen” instead of the exact CCSD schedule wording is a common, avoidable query trigger.
• Billing under the wrong recognition grade. Chapter 34 has separate fee columns depending on the recognition held by the provider submitting the claim. Using a consultant’s personal recognition to bill a test actually performed by an unrecognized lab is a frequent, entirely avoidable rejection reason.

If you’re running MRD monitoring at any volume, a periodic audit of the billing workflow earns its place fast. The reassuring part is that compliance auditing habits port straight over from any other kind of claim: the specifics change, the discipline doesn’t. And given how much diagnosis-linked detail a genomic test’s paperwork carries, it’s worth holding to solid data protection practices while you’re at it.

How Pabau supports CCSD code billing for private specialist practices

Everything above is doable by hand. What makes it painful is the toggling — between the CCSD schedule, your own system, the insurer portal, and, for a code like 0040G, the clinical record that says which diagnosis and which monitoring round this claim belongs to. That’s four places to keep in sync, per round, per patient.

Practice management software like Pabau exists to collapse that into one. It keeps CCSD code entry, the clinical record, and invoice generation on a single screen: you enter 0040G at the point the test is requested, linked to the referral and the diagnosis; it checks the claim for the missing pieces that trigger queries — authorization reference, membership number, matching wording — before anything is submitted through its Healthcode integration; and it tracks each round by test date so nothing blurs across a monitoring schedule.

If you’re billing across several insurers at once, it’s also where you’d keep an eye on your CCSD fee schedule coverage — a missed recognition update being a quietly common reason a 0040G claim bounces.

See CCSD pathology billing in one place

Pabau connects your clinical records, CCSD code selection, and Healthcode submission — including the diagnosis and consultant details a test like MRD sequencing needs to clear on the first pass.

Book a demo

Expert picks: UK private practice billing resources

Continue your research

Curious how other CCSD pathology codes are billed? 0037G covers Chapter 34 recognition and claims for the Mdm2 gene amplification test.

Billing a Lynch-syndrome-related genetic test? 0029B covers the MLH1 promoter hypermethylation test and its CCSD recognition.

Weighing a move into private practice? Benefits of private practice breaks down the financial and clinical upsides UK doctors cite most often.

Conclusion

Strip it back and 0040G is simple to hold in your head: it’s the CCSD code for MRD genomic sequencing in blood cancers, a test that hands hematologists and oncologists a sensitivity conventional monitoring can’t reach, billed inside Chapter 34 (Pathology).

Two things are worth carrying away. First, the placement: Chapter 34 codes don’t follow the schedule’s usual structure, and 0040G’s exact specimen-level slot isn’t published anywhere public — so confirm it against the official CCSD schedule or the insurer rather than assuming where a genomic test “ought” to live.

Second, the rejections that hurt most are the ones easiest to prevent: a pre-authorization missing the diagnosis it’s tied to, invoice wording that drifts from the official schedule description, and a claim raised by a lab that isn’t itself recognized for Chapter 34 pathology. Get those three right, round after round, and 0040G stops being the claim you dread and becomes the one that just clears.

Frequently asked questions